Guidance on Placement of Integrated Effectiveness and Safety Summaries; Advice from FDA on Presenting Risk Information; More Warnings for Erlotinib; Sanofi-Aventis Said to Overstate Efficacy of Docetaxel; Possible Dosage Alterations for Rituximab; FDA Establishes Transparency Task Force; Unauthorized Clinical Trials Alleged; FDA Should Release Information on Unapproved Uses; Pegylated Anti-TNF Product Closer to European Approval; Viral Contaminant Reducing Supplies of

doi:10.1089/blr.2009.9925

Guidance on Placement of Integrated Effectiveness and Safety Summaries; Advice from FDA on Presenting Risk Information; More Warnings for Erlotinib; Sanofi-Aventis Said to Overstate Efficacy of Docetaxel; Possible Dosage Alterations for Rituximab; FDA Establishes Transparency Task Force; Unauthorized Clinical Trials Alleged; FDA Should Release Information on Unapproved Uses; Pegylated Anti-TNF Product Closer to European Approval; Viral Contaminant Reducing Supplies of

https://doi.org/10.1089/blr.2009.9925

Copy DOI

Journal: Biotechnology Law Report

Publication Date: Aug 1, 2009

#Human Embryonic Stem Cell Lines #Presenting Risk Information + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Guidance on Placement of Integrated Effectiveness and Safety Summaries; Advice from FDA on Presenting Risk Information; More Warnings for Erlotinib; Sanofi-Aventis Said to Overstate Efficacy of Docetaxel; Possible Dosage Alterations for Rituximab; FDA Establishes Transparency Task Force; Unauthorized Clinical Trials Alleged; FDA Should Release Information on Unapproved Uses; Pegylated Anti-TNF Product Closer to European Approval; Viral Contaminant Reducing Supplies of

Full Text